News AI predicts liver cancer risk with "high accuracy" A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
News Corcept gets FDA OK for first-in-class ovarian cancer drug Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.
News Update: Rumour confirmed as MSD buys Terns for $6.7bn MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.
News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
News Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
News Dizal breaks new ground for EGFR drugs in lung cancer Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.